Editas Medicine (EDIT) Tops Q1 EPS by 15c

Editas Medicine (NASDAQ: EDIT) reported Q1 EPS of ($0.67), $0.15 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $3.9 million versus the consensus estimate of $3.99 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Credo Tech (CRDO) PT Lowered to $245 at Mizuho
• Corpay agrees to $100M FTC settlement over marketing practices